Pharmaceutical - Antibiotics and Infectious diseases, GlaxoSmithKline

Filter

Popular Filters

Tamiflu use called into question by UK report

Tamiflu use called into question by UK report

10-04-2014

The UK government and health policy decision makers are being called upon to review the guidance on the…

Antibiotics and Infectious diseasesChemistryDavid ToveyGlaxoSmithKlineHealthcareMajorPharmaceuticalRelenzaResearchRocheTamifluThe British Medical JournalUKUK government

GSK’s Synflorix gets additional indication in Europe

GSK’s Synflorix gets additional indication in Europe

05-12-2013

The European Commission has granted marketing authorization for an additional indication for UK pharma…

Antibiotics and Infectious diseasesEuropeGlaxoSmithKlinePharmaceuticalRegulationSynflorix

Case study draws attention to innovator brand preferences in Kenya

08-10-2013

Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

GlaxoSmithKline gets $200 million BARDA award to develop new antibiotics

22-05-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and the Biomedical Advanced Research and Development Authority…

Antibiotics and Infectious diseasesFinancialGlaxoSmithKlinePharmaceuticalResearch

GlaxoSmithKline and Abbott to start production in Ukraine

19-03-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and the USA's Abbott (NYSE: ABT) are considering launching…

Anti-viralsAntibiotics and Infectious diseasesEuropeGlaxoSmithKlineIndarPharmaceuticalProductionVaccines

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK

20-12-2012

NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

US FDA approvals for Signifor, raxibacumab and Iclusig

17-12-2012

In a flurry of activity from the US Food and Drug Administration on Friday, the agency - which looks…

Antibiotics and Infectious diseasesAriad PharmaceuticalsGlaxoSmithKlineIclusigNorth AmericaNovartisOncologyPharmaceuticalRare diseasesraxibacumabRegulationSignifor

GlaxoSmithKline amends accord with Isis Pharma; gets FDA panel backing for raxibacumab

06-11-2012

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) says it has agreed to amend the clinical development plan…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesraxibacumabRegulationResearch

Further initiatives from GlaxoSmithKline to help tackle global health challenges; TB deal with Aeras

12-10-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) yesterday announced new measures to further advance its commitment…

Antibiotics and Infectious diseasesGlaxoSmithKlineGlobalHealthcarePharmaceuticalResearchVaccines

AstraZeneca gains rights to Ardelyx program; GSK returns cUTI candidate GSK2251052 to Anacor

08-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning announced a worldwide exclusive licensing…

Anacor PharmaceuticalAntibiotics and Infectious diseasesArdelyxAstraZenecaGastro-intestinalsGenito-urinaryGlaxoSmithKlineGSK2251052LicensingNephrology and HepatologyPharmaceuticalRDX5791Research

News briefs: GlaxoSmithKline and Bayer

24-05-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile…

Antibiotics and Infectious diseasesBayerGlaxoSmithKlineMergers & AcquisitionsOncologyPharmaceuticalregorafenibRegulationResearch

GlaxoSmithKline pauses four UTI drug trials

07-02-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) has voluntarily paused enrollment in its current clinical…

Anacor PharmaceuticalAntibiotics and Infectious diseasesGlaxoSmithKlinePharmaceuticalResearch

Back to top